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Abstract: Carbon monoxide (CO) produced by heme oxygenase (HO)-1 and HO-2 or released
from the CO-donor, tricarbonyldichlororuthenium (II) dimer (CORM-2) causes vasodilation, with
unknown efficacy against stress-induced gastric lesions. We studied whether pretreatment with
CORM-2 (0.1–10 mg/kg oral gavage (i.g.)), RuCl3 (1 mg/kg i.g.), zinc protoporphyrin IX (ZnPP)
(10 mg/kg intraperitoneally (i.p.)), hemin (1–10 mg/kg i.g.) and CORM-2 (1 mg/kg i.g.) combined
with NG-nitro-L-arginine (L-NNA, 20 mg/kg i.p.), 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ,
10 mg/kg i.p.), indomethacin (5 mg/kg i.p.), SC-560 (5 mg/kg i.g.), and celecoxib (10 mg/kg i.g.)
affects gastric lesions following 3.5 h of water immersion and restraint stress (WRS). Gastric blood
flow (GBF), the number of gastric lesions and gastric CO and nitric oxide (NO) contents, blood
carboxyhemoglobin (COHb) level and the gastric expression of HO-1, HO-2, hypoxia inducible factor
1α (HIF-1α), tumor necrosis factor α (TNF-α), cyclooxygenase (COX)-2 and inducible NO synthase
(iNOS) were determined. CORM-2 (1 mg/kg i.g.) and hemin (10 mg/kg i.g.) significantly decreased
WRS lesions while increasing GBF, however, RuCl3 was ineffective. The impact of CORM-2 was
reversed by ZnPP, ODQ, indomethacin, SC-560 and celecoxib, but not by L-NNA. CORM-2 decreased
NO and increased HO-1 expression and CO and COHb content, downregulated HIF-1α, as well as
WRS-elevated COX-2 and iNOS mRNAs. Gastroprotection by CORM-2 and HO depends upon CO’s
hyperemic and anti-inflammatory properties, but is independent of NO.
Keywords: carbon monoxide; stress; nitric oxide; gastroprotection; gastric blood flow; heme
oxygenase-1; cyclooxygenases; soluble guanylyl cyclase; hypoxia inducible factor 1α
1. Introduction
Carbon monoxide (CO), previously regarded as a metabolic waste, is now considered as a gaseous
molecule exerting important signaling functions in the body [1,2]. CO can be produced by the actions of
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two microsomal proteins: induced by stress, heme oxygenase (HO)-1 and the constitutively expressed
isoform, HO-2 [3]. Sensing gaseous molecules such as oxygen (O2), nitric oxide (NO) and CO are
distinctive features of living organisms and are predominantly mediated by heme-based sensors [4].
Most of the actions of CO are exerted through the binding of CO to ferrous iron (Fe2+) and subsequent
alteration of the functions of the hemoproteins [5,6]. CO competes with O2 for metalloproteins such as
hemoglobin (Hb), myoglobin, cytochrome c oxidase and cytochrome P-450 [7,8].
Formation of carboxyhemoglobin (COHb) negatively impacts the two main functions of Hb by
decreasing the O2 carrying capacity of blood and impairing the release of O2 from Hb to tissues [9].
CO has been shown to inhibit cytochrome c oxidase in vitro, and thus significantly inhibiting cellular
respiration [10]. The interaction of CO with cytochrome P-450 in liver microsomes results in the
inhibition of enzymatic activity of this protein [11]. CO, which binds to the heme moiety at the active
site of soluble guanylyl cyclase (sGC), has been shown to activate sGC by about four-fold, thereby
elevating intracellular levels of the second messenger molecule, cyclic guanosine 31,51-monophosphate
(cGMP) [12]. Recently, CO has been implicated in the mechanism of gastric integrity by exhibiting
sGC-activation-dependent gastroprotective effects against ethanol-induced gastric damage [13–15].
CO can form complexes with a reduced form of another metalloprotein, inducible NO synthase (iNOS),
which is considered a pro-inflammatory marker. Activity of iNOS can be directly inhibited by CO,
which is known to bind to the heme moiety of the enzyme [16–18]. Moreover, both cyclooxygenase
(COX) isoforms, COX-1 and COX-2 are hemoproteins, which remain potential targets of CO [19,20]. The
two COX isoforms are key enzymes required for the conversion of arachidonic acid to prostaglandins
(PGs) [19,20]. Heme degradation subsequently begins with the generation of the ferric heme-HO
complex [21]. Due to spectral similarities of heme-HO complex and both ferric myoglobin and Hb,
HO seems to be another notable target of CO [22,23].
Recent studies in the field of gastrointestinal (GI) pathophysiology have consistently focused
on the gastroprotective involvement of CO, NO and hydrogen sulfide (H2S) in various preclinical
animal models of gastric mucosal lesion formation [24–27]. Moreover, Tavares et al. demonstrated that
treatment with CO-releasing molecules (CORMs) is effective against gastric colonization by antibiotic
resistant strains of Helicobacter pylori [28]. Restoration of delayed gastric emptying in diabetic mice
to normal rates by inhalation of a low dose of CO was confirmed by Kashyap et al. [29]. Additionally,
CO is involved in both PG-mediated stimulation of HCO3´ secretion in the duodenum [30] as well
as protection against ethanol- and alendronate-induced gastric lesions [13–15]. CO seems to be an
important factor involved in the mechanism of gastric mucosal defense, but the contribution of this
gaseous molecule to gastroprotection against acute gastric lesions induced by water immersion
and restraint stress (WRS) has not been explored [31,32]. WRS is a widely accepted model for
studying GI erosions, which mimics the clinical outcome of stress complication in the stomach [31,32].
In particular, the role of the HO/CO system in the pathogenesis of peptic ulcer disease is still not clear.
Therefore, we attempted in the present study to determine the effect of pretreatment with the CO
donor, tricarbonyldichlororuthenium (II) dimer (CO-releasing molecule, CORM-2) on gastric mucosal
injury induced by WRS. We examined the underlying mechanism of the potential protective action of
CO with a particular focus on the ability of CORM-2 to elevate CO level in gastric mucosa and COHb
concentration in whole blood. We also aimed to investigate other important factors involved in the
mechanism of gastric protection such as sGC/cGMP, NO/NO synthase (NOS) and PG/COX systems
by measuring both NO content in gastric tissues and changes in the mRNA expression of HO-1, HO-2,
hypoxia inducible factor 1α (HIF-1α) and pro-inflammatory factors tumor necrosis factor α (TNF-α),
COX-2 and iNOS in gastric mucosa following WRS.
2. Results
Figure 1 shows that pretreatment with CORM-2 administered by oral gavage (i.g.) in a dose of
0.1, 1 or 1.5 mg/kg significantly reduced (p < 0.05) WRS-induced gastric lesions. This gastroprotective
effect of CORM-2 against WRS-induced gastric lesions was accompanied by a significant increase in
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gastric blood flow (GBF) (p < 0.05). However, when CORM-2 was given in higher doses ranging from
2 to 10 mg/kg, both an increase in mean lesion number and a decrease in the GBF were observed
in comparison with lower doses, which were not significantly different from those observed in
vehicle-treated animals. Therefore, CORM-2 administered in the dose of 1 mg/kg, which reduced the
number of WRS-induced gastric lesions by about 50% was selected and subsequently used for further
studies to investigate the mechanism of CORM-2 protection against WRS-induced gastric damage.
Int. J. Mol. Sci. 2016, 17, 442 3 of 20 
 
2. Results 
Figure 1 shows that pretreatment with CORM-2 administered by oral gavage (i.g.) in a dose of 
0.1, 1 or 1.5 mg/kg significantly reduced (p < 0.05) WRS-induced gastric lesions. This gastroprotective 
effect of CORM-2 against WRS-induced gastric lesions was accompanied by a significant increase in 
gastric blood flow (GBF) (p < 0.05). However, when CORM-2 was given in higher doses ranging from 
2 to 10 mg/kg, both an increase in mean lesion number and a decrease in the GBF were observed  
in comparison with lower doses, which were not significantly different from those observed in 
vehicle-treated animals. Therefore, CORM-2 administered in the dose of 1 mg/kg, which reduced  
the number of WRS-induced gastric lesions by about 50% was selected and subsequently used  
for further studies to investigate the mechanism of CORM-2 protection against WRS-induced  
gastric damage. 
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of 6–8 animals for each experimental group. Asterisk indicates a significant change (p < 0.05) as 
compared with vehicle. 
Figure 2 shows that RuCl3 (1 mg/kg i.g.), a non-CO-releasing negative control [15,30], did not 
significantly affect WRS-induced gastric lesions and GBF. Zinc protoporphyrin IX (ZnPP, 10 mg/kg, 
intraperitoneally (i.p.)), a HO-1 inhibitor [33], failed to impact the number of WRS-induced gastric 
lesions and GBF. However, concurrent treatment of ZnPP with CORM-2 completely reversed the 
CORM-2-induced decrease in WRS-induced gastric lesions and the accompanying increase in GBF  
(p < 0.05) (Figure 2). 
Figure 3 shows the effect of pretreatment with vehicle (saline) or hemin, a HO-1 inducer [34], 
given i.g. in doses ranging from 1 up to 10 mg/kg on the mean lesion number and GBF in rats 
exposed to 3.5 h of WRS. Pretreatment with hemin administered in a dose of 1 or 5 mg/kg failed to 
affect the mean lesion number and GBF; however, when hemin was applied in the higher dose of  
10 mg/kg, it significantly reduced (p < 0.05) the number of WRS-induced gastric lesions. This last 
effect was accompanied by a significant increase in GBF (p < 0.05). 
Figure 1. Mean lesion number and gastric blood flow (GBF) in gastric mucosa pretreated with vehicle
(saline; oral gavage (i.g.)) or carbon monoxide releasing molecule 2 (CORM-2, 0.1–10 mg/kg i.g.) and
compromised 30 min later by water immersion and restraint stress (WRS). Results are mean ˘ S.D. of
6–8 animals for each experimental group. Asterisk indicates a significant change (p < 0.05) as compared
with vehicle.
Figure 2 shows that RuCl3 (1 mg/kg i.g.), a non-CO-releasing negative control [15,30], did not
significantly affect WRS-induced gastric lesions and GBF. Zinc protoporphyrin IX (ZnPP, 10 mg/kg,
intraperitoneally (i.p.)), a HO-1 inhibitor [33], failed to impact the number of WRS-induced gastric
lesions and GBF. However, concurrent treatment of ZnPP with CORM-2 completely reversed the
CORM-2-induced decrease in WRS-induced gastric lesions and the accompanying increase in GBF
(p < 0.05) (Figure 2).
Figure 3 shows the effect of pretreatment with vehicle (saline) or hemin, a HO-1 inducer [34],
given i.g. in doses ranging from 1 up to 10 mg/kg on the mean lesion number and GBF in rats exposed
to 3.5 h of WRS. Pretreatment with hemin administered in a dose of 1 or 5 mg/kg failed to affect the
mean lesion number and GBF; however, when hemin was applied in the higher dose of 10 mg/kg,
it significantly reduced (p < 0.05) the number of WRS-induced gastric lesions. This last effect was
accompanied by a significant increase in GBF (p < 0.05).
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Figure 2. Mean lesion number and gastric blood flow (GBF) in gastric mucosa pretreated with vehicle
(saline; i.g.; yellow pattern), RuCl3 (1 mg/kg i.g.; mosaic patttern), carbon monoxide releasing molecule
2 (CORM-2, 1 mg/kg i.g.; brick pattern) and zinc protoporphyrin IX (ZnPP, 10 mg/kg, intraperitoneally
(i.p.); brick pattern) administered alone or in combination with CORM-2 and compromised 30 min
later by water immersion and restraint stress (WRS). Results are mean ˘ S.D. of 6–8 animals for
each experimental group. Asterisk indicates significant change (p < 0.05) as compared with vehicle
(saline). Cross indicates significant change (p < 0.05) as compared with the group treated with CORM-2
(1 mg/kg i.g.) alone.
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Figure 3. Mean lesion number and gastric blood flow (GBF) in gastric mucosa pretreated i.g. with
vehicle (saline) or hemin administered in increasing doses ranging from 1 up to 10 mg/kg i.g. and
exposed 30 min later to water immersion and restraint stress (WRS). Results are mean ˘ S.D. of
4–6 animals for each experimental group. Asterisk indicates significant change (p < 0.05) as compared
with vehicle (saline).
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Figure 4 shows a simultaneous significant decrease (p < 0.05) in the number of WRS-induced
gastric lesions and a significant increase (p < 0.05) in the CORM-2 (1 mg/kg i.g.) group as compared
with the vehicle (saline) pretreated group. This is a similar finding to those shown in Figures 1
and 2. Co-administration of CORM-2 with NG-nitro-L-arginine (L-NNA, 20 mg/kg i.p.), an inhibitor
of NOS [35], did not cause the reduction of WRS damage elicited by this CO donor (Figure 3).
Nevertheless, concomitant treatment with CO and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ,
10 mg/kg i.p.), which is the irreversible and highly selective inhibitor of sGC [36], reversed
CORM-2-induced gastroprotection and significantly decreased GBF (p < 0.05) as compared with
the control group treated with this CO donor alone (Figure 4).
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Figure 5 shows representative photomicrographs of gastric mucosa of rats pretreated i.g. with 
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dot-like hemorrhagic gastric lesions were observed in vehicle-treated rats, but pretreatment with 
CORM-2 reduced these lesions (Figure 5A vs. Figure 5B). In contrast, concurrent administration of 
L-NNA (20 mg/kg i.p.) in combination with this CO donor failed to produce the gastric lesion 
reduction, which had been evoked by CORM-2 alone (Figure 5C vs. Figure 5B). Moreover, in the 
gastric mucosa of rats with concomitant administration of CORM-2 with ODQ (10 mg/kg i.p.) or 
ZnPP (10 mg/kg i.p.), the number of gastric lesions increased as compared with that observed in 
CORM-2-pretreated gastric mucosa (Figure 5D,E vs. Figure 5B). 
Figure 4. Mean lesion number and gastric blood flow (GBF) in gastric mucosa pretreated i.g. with
vehicle (saline; yellow pattern), carbon monoxide releasing molecule 2 (CORM-2, 1 mg/kg i.g.) applied
alone (mosaic pattern) or in combination with NG-nitro-L-arginine (L-NNA, 20 mg/kg i.p.; line pattern)
or 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10 mg/kg i.p.; brick pattern) and followed
by water immersion and restraint stress (WRS). Results are mean ˘ S.D. of 6–8 animals for each
experimental group. Asterisk indicates significant change (p < 0.05) as compared with vehicle (saline).
Cross indicates significant change (p < 0.05) as compared with the group pretreated with vehicle (saline)
and administered with CORM-2 (1 mg/kg i.g.).
Figure 5 shows representative photomicrographs of gastric mucosa of rats pretreated i.g. with
vehicle (saline; Figure 5A) or CORM-2 (1 mg/kg i.g.; Figure 5B) following WRS. Numerous typical
dot-like hemorrhagic gastric lesions were observed in vehicle-treated rats, but pretreatment with
CORM-2 reduced these lesions (Figure 5A vs. Figure 5B). In contrast, concurrent administration
of L-NNA (20 mg/kg i.p.) in combination with this CO donor failed to produce the gastric lesion
reduction, which had been evoked by CORM-2 alone (Figure 5C vs. Figure 5B). Moreover, in the
gastric mucosa of rats with concomitant administration of CORM-2 with ODQ (10 mg/kg i.p.) or
ZnPP (10 mg/kg i.p.), the number of gastric lesions increased as compared with that observed in
CORM-2-pretreated gastric mucosa (Figure 5D,E vs. Figure 5B).
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Figure 5. Gastric mucosa of rats exposed to water immersion and restraint stress (WRS) pretreated
with vehicle (saline; i.g.) (A); Carbon monoxide releasing molecule 2 (CORM-2, 1 mg/kg i.g.)
applied alone (B); or in combination with NG-nitro-L-arginine (L-NNA, 20 mg/kg i.p.) (C);
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10 mg/kg i.g.) (D); or zinc protoporphyrin IX
(ZnPP, 10 mg/kg i.p.) (E). Note, the presence of hemorrhagic gastric lesions in the gastric mucosa of
rats pretreated with vehicle (control) and exposed to 3.5 h of WRS (A). These macroscopic lesions were
reduced by CORM-2 (B) were not affected by concurrent treatment of L-NNA (C) but increased in
CORM-2-pretreated rats concomitantly treated with ODQ (D) or ZnPP (E).
Figure 6 shows that CORM-2 (1 mg/kg i.g.) caused a significant reduction in WRS-lesion number
as well as an increase in GBF, similarly as demonstrated in Figures 1, 2 and 4. Administration of
indomethacin (5 mg/kg i.p.), SC-560 (5 mg/kg i.g.) or celecoxib (10 mg/kg i.g.), non-selective and
selective COX-1 or COX-2 inhibitors [37], respectively, prior to CORM-2 (1 mg/kg i.g.) significantly
increased (p < 0.05) WRS-induced lesions and decreased GBF compared to respective values obtained
in rats pretreated with this CO donor alone (Figure 6).
Figure 7A shows the gastric mucosal CO content and COHb concentration in blood of rats
pretreated with vehicle (saline) or CORM-2 (1 mg/kg i.g.). The CO content in the gastric mucosa
and COHb concentration in blood were significantly increased (p < 0.05) after CORM-2 (1 mg/kg
i.g.) administration, as compared with vehicle-treated animals (Figure 7A). The content of CO in
the gastric mucosa pretreated with vehicle (saline), RuCl3, CORM-2 or ZnPP and exposed 30 min
later by WRS is presented in Figure 7B. In rats pretreated with vehicle (saline), CO content was not
significantly affected as compared with intact animals (Figure 7B). The gastric mucosal content of CO
in rats pretreated with RuCl3 (1 mg/kg i.g.) or CORM-2 (1 mg/kg i.g.) 30 min before exposure to
WRS failed to show a significant difference as compared with the vehicle-treated group (Figure 7B).
However, ZnPP (10 mg/kg i.p.) significantly decreased (p < 0.05) the CO gastric mucosal content in
rats compromised by WRS as compared with the vehicle-treated group (Figure 7B).
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vehicle (saline; yellow pattern), carbon monoxide releasing molecule 2 (CORM-2, 1 mg/kg i.g.) alone
(mosaic pattern) or administered in combination with non-selective cyclooxygenase (COX) inhibitor,
indomethacin (5 mg/kg i.p.; line pattern), selective COX-1 inhibitor, SC-560 (5 mg/kg i.g.; brick
pattern) or selective COX-2 inhibitor, celecoxib (10 mg/kg i.g.; brick pattern) and 30 min later exposed
to 3.5 h of water immersion and restraint stress (WRS). Results are mean ˘ S.D. of 6–8 animals for
each experim ntal group. Asterisk indicates significant change (p < 0.05) as compared with ve icle
(saline) controls. Cross indicates significant cha ge (p < 0.05) as compared with the group treated with
CORM-2 (1 mg/kg i.g.) alone.
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Figure 7. The gastric mucosal content of carbon monoxide (CO) and carboxyhemoglobin (COHb)
concentration in rats treated i.g. with vehicle (saline; yellow pattern) and CORM-2 (1 mg/kg; line
pattern) (A); and the gastric mucosal CO content in intact rats (yellow pattern) and in rats pretreated
with vehicle (saline; i.g.; line pattern), RuCl3 (1 mg/kg i.g.; brick pattern), CO releasing molecule 2
(CORM-2 ,1 mg/kg i.g.; brick pattern) and zinc protoporphyrin IX (ZnPP, 10 mg/kg i.p.; brick pattern)
30 min before the exposure to 3.5 h of water immersion and restraint stress (WRS) (B). Results are mean
˘ S.D. of 4–5 animals for each experimental group. Asterisk indicates significant change (p < 0.05) as
compared with vehicle-treated groups.
Figure 8 shows that CORM-2 administered in a dose of 1 mg/kg i.g. significantly ecreased
(p < 0.05) NO concentrations in gastric mucosa of rats exposed to WRS as compared with vehicle-treated
rats. The gastric mucosal NO content in intact animals was 3.2 ˘ 0.9 µM and significantly elevated
(p < 0.05) to 4.4 ˘ 1.2 µM in the gastric mucosa of rats pretreated with vehicle (saline) and exposed
to WRS. Pretreatment with RuCl3 (1 mg/kg i.g.) failed to impact NO content in the gastric mucosa
compromised by WRS as compared with the vehicle-treated group, while ZnPP administered in a dose
of 10 mg/kg i.p. did not significantly change gastric NO content as compared with vehicle treated rats
(Figure 8).
Figure 9 shows mRNA expression levels of HO-1 (Figure 9A,B) and HO-2 (Figure 9C,D) in the
gastric mucosa of both intact rats and those pretreated with saline (vehicle), hemin (10 mg/kg i.g.;
Figure 9B), or CORM-2 (1 mg/kg i.g.) alone or combined with L-NNA (20 mg/kg i.p.) and subsequently
exposed to WRS (Figure 9A). In vehicle-treated rats exposed to WRS, a significant increase (p < 0.05) in
gastric mucosal mRNA expression of HO-1 was observed as compared with intact rats (Figure 9A,B).
Pretreatment with hemin (10 mg/kg i.g.) or CORM-2 (1 mg/kg i.g.) significantly increased (p < 0.05)
HO-1 mRNA expres ion over that of v hicle-treated rats xposed to WRS. This effect of the CO d nor
was not ignificantly affected by L-NNA (Figure 9A,B). Expression of HO-2 mRNA was s gnificantly
decreased (p < .05) in vehicle-pretreat d ats who were exposed to WRS as compared with intact
animals (Figure 9C,D). CORM-2 (1 mg/kg i.g.) r hemin administered in a dose of 10 mg/kg i.g.
applied alone or combined with L-NNA (20 mg/kg i.p.) did not change the downregulation of HO-2
mRNA expression observed in vehicle-control rats exposed to WRS (Figure 9C,D).
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Figure 8. The gastric mucosal nitric oxide (NO) content in rats pretreated i.g. with vehicle (saline;
yellow pattern), RuCl3 (1 mg/kg; brick pattern), carbon monoxide releasing molecule 2 (CORM-2,
1 mg/kg; brick pattern) or zinc protoporphyrin IX (ZnPP, 10 mg/kg i.p.; brick pattern) and exposed
30 min later to 3.5 h of water immersion and restraint stress (WRS). Results are mean ˘ S.D. of
4–5 animals in ach experimental group. Asterisk indicates significant change (p < 0.05) as compared
with vehicle-treated control group.
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Figure 9. Expression levels of mRNA for heme oxygenase (HO)-1 (A,B) and HO-2 (C,D) in the gastric
mucosa of intact rats (y llow pattern) or those pretreated with vehicle (salin ; i.g.; line pattern), hemin
(10 mg/kg i.g.; dot pattern) or carbon monoxide releasing molecule 2 (CORM-2, 1 g/kg i.g.) alone
(line pattern) or administered in combination with NG-nitro-L-arginine (L-NNA, 20 mg/kg i.p.; brick
pattern) and exposed to 3.5 h of water immersion a d restraint stress (WRS). Results are expressed
as mRNA express of HO-1 and HO-2 normalized to β-actin. Results re ean ˘ S.D. of 6–8
determinations per group. Asterisk indicates a significant change (p < 0.05) as compared with the
respective values in intact gastric mucosa. Cross indicates significant change (p < 0.05) as compared
with the values obtained for the vehicle-treated group.
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Figure 10 shows mRNA expression levels of HIF-1α in the gastric mucosa of both intact rats
and those pretreated with either vehicle (saline) or CORM-2 (1 mg/kg i.g.), which were applied with
or without combination with L-NNA (20 mg/kg i.p.) and subsequently exposed to 3.5 h of WRS.
In vehicle-treated gastric mucosa, a significant increase (p < 0.05) in gastric mucosal HIF-1α mRNA
expression was observed as compared with intact rats (Figure 10). CORM-2, applied either alone or
administered in combination with L-NNA significantly decreased (p < 0.05) HIF-1α mRNA expression
as compared with the vehicle-control group (Figure 10).
As shown in Figure 11A–C, the gastric mucosal mRNA expression of iNOS (Figure 11A), COX-2
(Figure 11B) or TNF-α (Figure 11C) was significantly augmented in vehicle-treated control gastric
mucosa as compared with those detected in intact rats. CORM-2 (1 mg/kg i.g.) administered alone
or in combination with L-NNA (20 mg/kg i.p.) significantly decreased (p < 0.05) mRNA expression
for iNOS (Figure 11A) and COX-2 (Figure 11B) as compared with vehicle-treated gastric mucosa
(Figure 11A,B). Pretreatment with CORM-2 (1 mg/kg i.g.) did not significantly influence the rise in
mRNA expression for TNF-α observed in vehicle-treated rats exposed to WRS (Figure 11C).
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Figure 10. Expression levels of hypoxia inducible factor 1α (HIF-1α) mRNA in the gastric mucosa
of intact rats (yellow pattern) or those pretreated it vehicle (saline; i.g.; line pattern), carbon
monoxide releasing mol cule 2 (CORM-2, 1 i.g.; line pattern) alone r in combination with
NG-nitro-L-arginine (L-NNA, 20 mg/kg i.p.; brick pattern) and exposed to 3.5 h of water immersion
and restraint stress (WRS). Results are expressed as HIF-1α mRNA expression normalized to β-actin.
Results are mean ˘ S.D. of 6–8 determinations per group. Asterisk indicates a significant change
(p < 0.05) as compared with the respective values in intact gastric mucosa. Cross indicates a significant
hange (p < 0.05) as compared with the values obtained vehicle-treated group.
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Exposure of rats to acute stress is known to cause hemorrhagic gastric lesions in the stomach 
and mimics the clinical appearance of stress-induced peptic ulcers observed clinically in humans 
who suffer from burns, cold and life-threatening conditions [31,32,38]. Gastric hemorrhagic erosions 
following stress are sometimes called “stress ulcerations”. They have been attributed to hyperacidity 
resulting from changes in gastric acid secretion, hypermotility and increased permeability of the 
gastric mucosa to H+ ions involving deterioration of the microcirculation [39–41]. 
We observed that endogenous CO, produced due to the activity of HO or released from an 
exogenous chemical donor, CORM-2, administered i.g. in low doses ranging from 0.1 to 1.5 mg/kg, 
can attenuate the formation of acute stress-induced gastric lesions. This protective effect was 
accompanied by an increase in GBF, which in turn suggests a crucial role for the rise in the gastric 
microcirculation in this protection. Interestingly, we found that higher doses of CORM-2 from 2 up 
to 10 mg/kg were ineffective in gastroprotection against stress lesions. This finding likely suggests 
that increased amount of CORM-2-derived CO negatively impacted gastric cell respiration due to 
increased bioavailability of CO and COHb content in gastric mucosa and blood, respectively. Our 
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3. Discussion
Exposure of rats to acute stress is known to cause hemorrhagic gastric lesions in the stomach
and mimics the clinical appearance of stress-induced peptic ulcers observed clinically in humans
who suffer from burns, cold and life-threatening conditions [31,32,38]. Gastric hemorrhagic erosions
following stress are sometimes called “stress ulcerations”. They have been attributed to hyperacidity
resulting from changes in gastric acid secretion, hypermotility and increased permeability of the gastric
mucosa to H+ ions involving deterioration of the microcirculation [39–41].
We observed that endogenous CO, produced due to the activity of HO or released from an
exogenous chemical donor, CORM-2, administered i.g. in low doses ranging from 0.1 to 1.5 mg/kg, can
attenuate the formation of acute stress-induced gastric lesions. This protective effect was accompanied
by an increase in GBF, which in turn suggests a crucial role for the rise in the gastric microcirculation
in this protection. Interestingly, we found that higher doses of CORM-2 from 2 up to 10 mg/kg were
ineffective in gastroprotection against stress lesions. This finding likely suggests that increased amount
of CORM-2-derived CO negatively impacted gastric cell respiration due to increased bioavailability of
CO and COHb content in gastric mucosa and blood, respectively. Our previous study [15] revealed
that CORM-2 dose-dependently increased COHb concentration in blood and CO content in gastric
mucosa. Moreover, CORM-2 applied i.g. in a dose of 100 mg/kg exacerbated ethanol-induced gastric
lesions and markedly decreased GBF. These earlier findings suggested a strict dependence of this
gastroprotection and an increase in GBF on the dose of this CO donor [15]. Altogether, using the stress
model of gastric injury, we confirmed that the beneficial or noxious action of CORM-2 released CO
depends upon its administered dosage. The relevant dosage may in turn vary depending on the type of
injury, such in case of hemorrhagic ethanol damage or stress-induced mucosal erosions. Furthermore,
we found that mRNA expression for inducible HO-1 was upregulated and pretreatment with CORM-2
(1 mg/kg i.g.) further enhanced this effect in gastric mucosa compromised by WRS. Similarly to
our results, both Morsy et al. and Ibrahim et al. reported an increase in gastric HO-1 expression in
response to cold stress as determined by immunohistochemistry or enzyme-linked immunosorbent
assay (ELISA), respectively [42,43]. We observed that the HO-1 inducer, hemin, in the highest dose (10
mg/kg i.g.), reduced WRS-induced gastric lesions while simultaneously increasing GBF and HO-1
mRNA expression. These findings confirm our previous observation [15] that CORM-2 and hemin
administered in the dose of 5 mg/kg i.g., prevented gastric lesions induced by a corrosive agent,
such as ethanol via enhancement of GBF and upregulation for HO-1 mRNA expression by CORM-2.
Interestingly, mRNA expression for HO-2, which is expressed constitutively in parietal and gastrin
cells of the stomach [44], was downregulated in gastric mucosa that was compromised by WRS in
the current study. However, CORM-2 (1 mg/kg i.g.) or hemin, administered in protective dose of
10 mg/kg did not produce the same results. This finding implies that the gastroprotective mechanism
of CORM-2 against WRS damage involves the upregulation of HO-1 but not the HO-2, and that CO
derived from HO-1 can compensate for the decrease in HO-2 expression in stressed gastric mucosa.
Our previous study had revealed that protein expression for HO-2 was unchanged in gastric mucosa
compromised by ethanol but CORM-2 administered in gastroprotective dose of 5 mg/kg i.g. decreased
the protein expression level of this enzyme [15].
We previously attributed the gastroprotective effect of CORM-2 against ethanol-induced gastric
damage to the release of CO since COHb levels and the content of this gaseous mediator in gastric
mucosa were both increased after i.g. administration of CORM-2 in a dose of 5 mg/kg [15]. Similarly,
we have now observed that COHb levels and CO content in the gastric mucosa were increased after
CORM-2 application in a dose of 1 mg/kg. This increase conferred gastric mucosal protection against
stress-induced lesions accompanied by an increase in GBF. Moreover, we have demonstrated that
the application of RuCl3, employed as a non-CO-releasing negative control to CORM-2, which did
not confer protection against ethanol damage [15], failed to influence on the stress-induced gastric
lesions and accompanying alterations in GBF. This observation is corroborative with the observation by
Takeuchi et al. [45] who revealed that the beneficial effect of CORM-2 on protective alkaline bicarbonate
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secretion is solely due to CO generated from this compound because RuCl3 has been used by this
group of investigators as a negative control to CORM-2 and had no effect on this secretion. It is
therefore assumed that only CO released from CORM-2, but not ruthenium itself, is responsible for the
gastroprotective and hyperemic effects observed in our present study.
Additionally, administration of ZnPP, a non-selective HO inhibitor, decreased CO content in
gastric mucosa compromised by WRS, and also reversed the gastroprotective effect of CORM-2
when concomitantly administered with this CO donor. Therefore, we concluded that CO produced
from heme either by the HO-1/HO-2 pathway or released from CORM-2 exerts gastroprotective
activity in the gastric mucosa against stress-induced injury. ZnPP has been previously reported to
amplify ethanol- and hydrochloric acid-induced gastric damage [13,46], but in our present study
ZnPP failed to affect stress-induced gastric damage by itself. ZnPP did abolish the CORM-2-induced
gastroprotection against these lesions and also decreased CO content in gastric mucosa (Figure 7B)
possibly via inhibition of HO activity. Therefore, we concluded that CORM-2-induced-gastroprotection
could be mediated by both CO release and induction of HO-1 caused by this agent. The mechanism of
gastroprotection of CO produced by both CORM-2 and HO-1 should be further examined. Our finding
support the notion that CORM-2 in the protective dose used was not sufficient to counteract the deficit
in CO content resulting from the inhibition of HO by ZnPP. However, our observations using ZnPP in
the stress-injured rat stomach seem to be at variance with those by Ibrahim et al. [42] who reported
that 10 days of ZnPP administration reduced stress-induced gastric lesions. They had also concluded
that the protective effect of ZnPP against gastric ulcers induced by cold stress might be related to an
inhibition of gastric acidity and the availability of zinc from this HO inhibitor. These conclusions were
made despite the apparent inhibition of endogenous CO by ZnPP, while zinc has been shown to exert
gastroprotective and anti-ulcer effects. This discrepancy between our results and their observation [42]
may be due to different experimental conditions. Such difference include the combined method of
stress induction with the use of pylorus ligating for assessment of gastric acid secretion and exposure
to cold stress along with an experimental design, which included chronic (10 days) administration
of this HO inhibitor [42] vs. the application of ZnPP in a single dose prior to stress exposure in our
present work.
Interestingly, our present study revealed that CO protection against stress-induced acute gastric
injury is independent of NO since the blockade of NOS by the non-selective inhibitor, L-NNA [35],
failed to influence the protective effect of HO-derived and CORM-2-released CO. Moreover, we
demonstrated that CORM-2 administered in a protective dose of 1 mg/kg downregulated gastric
mucosal mRNA expression for iNOS in rats exposed to WRS. The administration of CORM-2 also
decreased NO content in gastric mucosa compromised by WRS. Inhibition of iNOS expression by CO
has been previously reported in LPS-stimulated macrophages by Srisook et al. and Sawle et al. [17,47]
who findings are partially in line with our observations. Therefore, it is reasonable to assume that
CO-induced gastroprotection against stress injury does not involve the contribution of NO activity in
CORM-2 protection against stress-induced gastric lesions. As shown before [15], this assumption could
not explain the mediatory role of NO in CORM-2-induced gastroprotection against ethanol injury.
This notion is supported by our recently published findings [15] that inhibition of NOS by L-NNA
reduced gastroprotection of CORM-2 against gastric damage induced by ethanol. This controversy
whether NO could mediate CO-induced protection should be further studied but we think that this
discrepancy may be due to the difference in the experimental models of gastric damage induced by
topically applied necrotizing agent ethanol vs. pleiotropic stress lesions induced by many non-topical
and local factors including ischemia, hypoxia and/or initiation of oxidative processes [38,48,49].
We have demonstrated that sGC inhibitor ODQ completely reversed CORM-2-induced
gastroprotection and an increase in GBF in the gastric mucosa compromised by WRS. This observation
suggests that CO-induced gastroprotection against stress injury and regulation of gastric
microcirculation may involve the activity of sGC/cGMP signaling pathway. This supports the previous
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findings [14,15] that sGC/cGMP pathway is involved in the protective effect of CO in alendronate-
and ethanol-induced gastric injury.
It has been shown that endogenous PGs produced by COX-1 and COX-2 expression and activity
are important components of gastric mucosal barrier [50–52]. These factors were proposed as keynote
mediators of gastroprotection involved in the maintenance of gastric mucosal integrity [50–52].
Thus, we hypothesized that PGs considered as classic cytoprotective agents [52], can mediate the
CO-induced gastroprotection and an increase in GBF in the rat stomach under stress conditions.
Herein, we demonstrated that non-selective (indomethacin) and selective COX-1 and COX-2 inhibitors
(SC-560 and celecoxib, respectively) reversed gastroprotective effect of CORM-2 and decreased GBF
elevated by this CO donor in the gastric mucosa compromised by WRS. This indicates that CO
released from CORM-2 can interact with classic gastroprotective arachidonate metabolites PGs in the
mechanism of gastroprotection and accompanying gastric mucosal hyperemia.
This study revealed that CO-mediated gastroprotection against stress-induced gastric lesions
involves the reduction of hypoxia documented by the decrease in mRNA expression for HIF-1α.
The pathophysiologic mechanism of the stress-induced gastric damage involves generation of reactive
oxygen species (ROS) [41], a well-recognized markers of the mucosal oxidative stress associated
with regulation of HIF-1α expression and lipid peroxidation in hypoxic gastric mucosa [53]. Indeed,
Gomes et al. [13] revealed that administration of CO-releasing dimanganese decacarbonyl (DMDC) or
induction of HO-1 by hemin decreased malonylodialdehyde (MDA) formation and increased reduced
glutathione (GSH) concentration in the gastric mucosa with ethanol-induced gastric damage. Moreover,
Costa et al. [14] demonstrated that DMDC decreased MDA concentrations, and also increased the
levels of GSH in gastric mucosa compromised by alendronate. Although not studied in our present
study, it seems likely that CORM-2 releasing CO-mediated reduction in ROS formation and lipid
peroxidation could contribute to the beneficial protective effect of this gaseous molecule observed in
gastric mucosa compromised by stress.
Moreover, we demonstrated that CO released from CORM-2 reduced inflammation since
pretreatment with CORM-2 (1 mg/kg i.g.) decreased mRNA expression for pro-inflammatory isoforms
COX-2 and iNOS in the gastric mucosa compromised by WRS. Our results are in agreement with
previously published reports regarding diminished iNOS [15,54–57] or COX-2 [15,52] expression in
the various disorders of upper GI tract. However, pretreatment with CORM-2 did not affect mRNA
expression for pro-inflammatory cytokine TNF-α, which is upregulated in the gastric mucosa exposed
to WRS. This observation remains in contrast to decreased TNF-α concentration in the gastric mucosa
of rats pretreated with CO donor and exposed to alendronate [14]. Again, this lack of influence of
CORM-2 on TNF-α expression could be due to different models of gastric injury alendronate vs.
stress and the duration time between the beginning and termination of the experiment in studies
with alendronate [14]. Interestingly, the inhibition of NOS by L-NNA had no effect whatsoever on
anti-hypoxic and anti-inflammatory activity of CO released from CORM-2 in the gastric mucosa
exposed to WRS because CORM-2-induced downregulation of local mRNA expression for HIF-1α,
COX-2 and iNOS was not modified by concurrent treatment with L-NNA. This observation supports
our conclusion that NO is not involved in the beneficial protective and hyperemic activity of CO
against stress lesions, which mainly depends upon the activation of the HO-1 pathway, sGC/cGMP
system and endogenous PGs by this vasoactive mediator.
4. Materials and Methods
4.1. Animals, Experimental Design, Chemicals and Drugs Treatment
Male Wistar rats with average weight 220–300 g were used in the experiments. Animals were
deprived of food for 24 h with free access to tap water before any application. All procedures were
approved by the Institutional Animal Care and Use Committee of Jagiellonian University Medical
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College in Cracow and in accordance with Helsinki Declaration (Application No.: 151/VIII/2012;
Decission No.: 137/2012; Date: 19 September 2012).
The experimental protocol and the sequence of procedures are depicted in Scheme 1.
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Scheme 1. Experimental protocol and sequence of performed procedures. WRS: water immersion and
restraint stress.
To induce gastric lesions by stress, rats were immobilized in individual Bolman’s cages and
immersed in the cold water (21 ˝C) for 3.5 h to the level of xiphoid cartilage as origin ly described by
Taka i et al. and in our previous studies [51,58].
Chemicals and drugs were administered i.p. or i.g. using an o ogastri tube as previously
reported [59].
Animals were randomly placed into six groups (A, B, C, D, E and F; 6–8 animals each) that were
retr a ed 30 min before xposure to WRS with appropriate chemicals and drugs.
In Group A, rats were treated with: (1) vehicle (salin ; 1 mL/rat i.g.) or (2) CORM-2
(Sigma-Aldrich, Schnelldorf, Germany) ad inistered .g. in doses ranging from 0.1 up to 10 mg/kg.
In Group B, rats were pretreated with: (1) vehicle (saline; i.g.); (2) RuCl3 (1 mg/kg i.g.,
Sigma-Aldrich) as negative control to CORM-2 [15,30,45]; (3) CORM-2 applied i.g. in a dose of
1 mg/kg which in our preliminary studies red ced stress-induced gastric lesions by about 50%
(series A); and (4) ZnPP (10 mg/kg i.p.), the HOs inhibitor [33], administered alone or in combination
with CORM-2.
In Group C, rats were pretreated with hemin, HO-1 inducer [34], applied i.g., in doses ranging
from 1 to 10 mg/kg.
Rats of Group D were pretreated with: (1) L-NNA (20 mg/kg i.p.), non-selective NOS inhibitor [35];
or (2) ODQ (10 mg/kg i.p., Sigma-Aldrich), a sGC inhibitor [36], 30 min before CORM-2 (1 mg/kg i.g.)
or vehicle (saline; i.g.) application.
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In Group E, animals were pretreated with: (1) vehicle (saline; i.g.); or (2) CORM-2 (1 mg/kg
i.g.) alone or in combination with the non-selective COX inhibitor, indomethacin (5 mg/kg i.p.,
Sigma-Aldrich) or the selective COX-1 inhibitor, SC-560 (5 mg/kg i.g., Cayman Chemical, Ann Arbor,
MI, USA), or celecoxib (10 mg/kg i.g., Pfizer, Illertissen, Germany), a selective COX-2 inhibitor [37].
In order to determine the CO level in gastric mucosa and COHb concentrations in the blood
samples, rats of separate Group F were not exposed to WRS, but were treated i.g. with 1 mL of saline
or CORM-2 applied i.g. in a dose of 1 mg/kg.
4.2. Determination of Gastric Blood Flow (GBF) and Gastric Lesion Number
At the termination of 3.5 h of WRS (Groups A, B, C, D, E) or 30 min after i.g., saline or CORM-2
(1 mg/kg i.g.) application (Group F), rats were kept under pentobarbital (60 mg/kg i.p.) anesthesia in
order to open the stomachs for the GBF measurement using H2-gas clearance technique as described
previously [60]. Briefly, the GBF was assessed in the oxyntic part of the gastric mucosa not having
stress-induced mucosal lesions. Average values of three determinations were expressed as a percentage
of vehicle-treated gastric mucosa. Gastric lesion number in each rat stomach from Groups A, B, C,
D and E was determined blindly using computerized planimetry (Morphomat, Carl Zeiss, Berlin,
Germany) [37,61]. Gastric mucosal biopsies (about 500 mg each) were taken for determinations of CO
content and the remaining part of stomach was scraped off on ice, snap-frozen in liquid nitrogen and
stored at ´80 ˝C until further analysis [15]. The blood samples (about 3 mL each) were taken from the
vena cava for the measurement of COHb concentrations [15].
4.3. Measurement of Carbon Monoxide (CO) Content in Gastric Mucosa and Blood Carboxyhemoglobin
(COHb) Concentration Using Gas Chromatography (GC)
CO concentrations in the gastric mucosa and COHb levels in blood were determined using GC
based on method described previously [15,62]. Briefly, the method is based on CO release from Hb
due to the change in the oxidation of Fe ion from +2 to +3 localized in the porphyrin ring center
and the catalytical conversion of CO to CH4, which was quantified by the use of flame ionization
detector (FID).
The detector response was expressed as CO volume using calibration curve assembled by adding
standards containing 0.0, 0.5, 1.0, 2.0, 5.0, 10.0, 20.0 and 50.0 mL of CO. Due to differences in Hb level
in particular blood samples and low values of COHb concentrations, it was necessary to construct
the calibration curve separately for each blood investigated, as described in details previously [62].
Briefly, standard solutions containing 100% of COHb were obtained after complete saturation of
each blood sample with CO and subsequently diluted with water to obtain solutions containing
10.0%, 7.5%, 5.0%, 2.5% and 0.0% of COHb. Standards for each calibration level were prepared
in triplicate. Chromatographic separation was performed in isothermal mode and appropriate
instrumental parameters of the headspace GC-FID method using column packed with molecular
sieves [15].
4.4. Determination of Nitric Oxide (NO) Content in Gastric Mucosa
Tissue biopsies stored at ´80 ˝C were homogenized with a cold phosphate-buffered saline
(Polfa, Kutno, Poland), centrifuged (3000 rpm, 15 min, 4 ˝C) and the supernatant was used for
further analysis. Before nitrite (NO2)´ and nitrate (NO3)´ determination, samples were normalized
for protein concentration using the standard Bradford reaction (Sigma-Aldrich). NO levels were
quantified using an Arrowstraight™ Nitric Oxide measurement system (Lazar Research Laboratories,
Los Angeles, CA, USA), which contained micro ion selective electrodes for independent measures
of both nitrite and nitrate in 100 µL of sample. As a standard, the sodium nitrite and sodium nitrate
were used (Sigma-Aldrich, Natick, MA, USA; for both). All procedures were conducted according to
the manufacturer’s protocol. Results were presented as a total NO (µM) calculated by summing the
concentration values of (NO2)´ and (NO3)´.
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4.5. Determination of mRNA Expression Levels for Heme Oxygenase (HO)-1, HO-2, Hypoxia Inducible Factor
1α (HIF-1α), Cyclooxygenase (COX)-2, Inducible NO Synthase (iNOS) and Tumor Necrosis Factor α (TNF-α)
in Gastric Mucosa
Expression levels of mRNA in gastric mucosa were determined by real-time polymerase chain
reaction (qPCR) as described previously [15]. Briefly, RNA was isolated from gastric mucosal biopsies
using GeneMATRIX Universal RNA Purification Kit (EURx, Gdansk, Poland). High-Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientific, Cambridge, MA, USA) was used to perform
reversed transcription to cDNA. Expression levels of HO-1, HO-2, HIF-1α, TNF-α, COX-2, iNOS and
β-actin as an internal control were determined using specific primers presented in Table 1, SG qPCR
Master Mix (2ˆ) including SYBR-Green (EURx, Gdansk, Poland) and thermal cycler 7900HT Fast
Real-Time PCR System (Thermo Fisher Scientific). Results were analyzed using the 2´∆Ct method [63].
Table 1. Forward and reverse primers used in real-time PCR reaction to assess mRNA expression for
β-actin, heme oxygenase (HO)-1, HO-2, hypoxia inducible factor 1α (HIF-1α), inducible nitric oxide
synthase (iNOS), cyclooxygenase (COX)-2 and tumor necrosis factor α (TNF-α).









Results are expressed as mean ˘ S.D. Statistical comparison was performed by Mann–Whitney
U-test or Student’s t-test. Analysis of variance (ANOVA) with Tukey post-hoc or Kruskal–Wallis with
Dunns post-hoc test where used where appropriate. p < 0.05 was considered significant.
5. Conclusions
We conclude that CO produced endogenously via heme degradation or CO released
from a chemical donor, CORM-2, can confer protection against stress-induced mucosal lesions.
The mechanism of CO gastroprotection may involve the regulation of gastric microcirculation due
to activation of the sGC/GMP system as well as anti-hypoxic and anti-inflammatory actions of this
gaseous molecule. Moreover, we have demonstrated that CO gastroprotection against stress-induced
gastric lesions could be mediated by endogenous PGs, the cytoprotective products of arachidonate
metabolism regulated by the activity of metalloproteins, COX-1 and COX-2 and the reciprocal increase
in expression of protective enzyme HO-1 observed in the gastric mucosa compromised by stress.
Furthermore, the CO-induced gastroprotection against stress damage seems to be independent of NO,
which is another important gaseous mediator. However, the mechanism of interaction among CO, NO
and another potent gaseous molecule, H2S [64], in the gastric mucosal defense against stress requires
confirmation in further studies.
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